SCHEMBL23354520

SCHEMBL23354520

Cc1cc(C(F)(F)F)cc(-c2ccc(C(F)(F)F)cc2)c1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.51
RXRB P28702 3/20 0.51
APP P05067 2/20 0.49
BACE1 P56817 1/20 0.48
CYP2C8 P10632 1/20 0.47
PSEN1 P49768 1/20 0.47
PSEN2 P49810 1/20 0.47
APH1B Q8WW43 1/20 0.47
NCSTN Q92542 1/20 0.47
APH1A Q96BI3 1/20 0.47
PSENEN Q9NZ42 1/20 0.47
RXRG P48443 2/20 0.46
DHODH Q02127 2/20 0.46
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 2/20 0.46
ADRB3 P13945 2/20 0.45
ADRA2B P18089 2/20 0.45
DRD1 P21728 2/20 0.45
DRD5 P21918 2/20 0.45
ADRA1B P35368 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31676846 1.00 RXRA (0.51) RXRARXRBAPPBACE1CYP2C8
SCHEMBL10058719 0.90 RXRA (0.51) RXRARXRBAPPBACE1CYP2C8
SCHEMBL6497035 0.83 BACE1 (0.47) RXRARXRBAPPBACE1CYP2C8
SCHEMBL422352 0.80 RXRA (0.51) RXRARXRBRXRGDHODHSRD5A2
SCHEMBL6639928 0.79 TACR1 (0.56) APPBACE1CYP2C8PSEN1PSEN2
SCHEMBL6799953 0.77 RXRA (0.55) RXRARXRBAPPBACE1CYP2C8
SCHEMBL2428750 0.76 CYP2C8 (0.56) RXRARXRBAPPBACE1CYP2C8
SCHEMBL2268521 0.76 CYP2C8 (0.60) RXRARXRBAPPBACE1CYP2C8
SCHEMBL593309 0.76 CYP2C8 (0.51) RXRARXRBAPPBACE1CYP2C8
SCHEMBL23354157 0.75 KDM4E (0.59) RXRARXRBAPPBACE1CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 RXRA 2875/4885RXRB 2822/4885APP 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.